---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-061834"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2026-09-14T20:07:12+00:00"
generated_at: "2026-09-14T20:08:29.901808+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Contineum's MOONLIGHT-1 Phase 2 trial fails primary endpoint in MDD

## Summary
- MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 in MDD did not meet primary efficacy endpoint.
- Primary endpoint: MADRS total score change at Day 5 vs placebo; no new safety signals.
- JNJ-5120/PIPE-307 developed by J&J under global license; J&J evaluating exploratory endpoints.
- Randomized, double-blind, placebo-controlled proof-of-concept trial in adult MDD (NCT06785012).

## SEC filing metadata
- accession: 0001628280-26-061834
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2026-09-14T20:07:12+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/0001628280-26-061834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/ctnm-20260914.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-061834
- JSON: https://secwatch.observer/filing/0001628280-26-061834.json
- Plain text: https://secwatch.observer/filing/0001628280-26-061834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.